Vocera Clinical Workflow Engine Improves Clinical Integrations and Reduces Costs

SAN JOSE, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Mobile healthcare communications company, Vocera (NYSE:VCRA), today introduced the Vocera Clinical Workflow Engine to streamline integrations between the Vocera Communication System and clinical systems such as nurse call and electronic health records (EHRs). By integrating Vocera with these and other solutions, hospitals can automatically send an alert to the nurse assigned to a particular patient based on the intelligent workflow defined in the system, improving patient safety and reducing the noise and annoyance of broadcast alarms.

Vocera's Clinical Workflow Engine eliminates the need for third-party middleware. It streamlines clinical workflows for voice, messaging, patient monitoring alerts and alarms, nurse calls, EHRs, bed management and other clinical systems. As part of the Vocera Communications System, this solution also reduces costs and the number of vendors required to support clinical workflows, simplifying care team collaboration.

A recent Vocera study sent to nearly 500 high-level hospital employees, conducted by TechValidate, showed 84 percent of respondents find value in Vocera integrations with patient monitoring; 75 percent find value in Vocera's ability to integrate with EHRs; and 87 percent indicated that Vocera integrations with nurse call systems were important.1 This workflow solution gives Vocera users the ability to deliver the right information, to the right person, on the right device, at the right time.

Using the Vocera Clinical Workflow Engine as the single source of information exchange improves accuracy and consistency within the communication data flow, and enables advanced workflow capabilities in reporting and analytics. For example, by integrating alert and alarm systems with the Vocera Clinical Workflow Engine, care teams can better understand alarm trends and identify potential workflow gaps with detailed analytics filtered by bed, unit, staff, alarm type, alarm density, distribution and response time. Between 72 and 99 percent of all clinical alarms do not require clinical intervention so this contextual data plays a crucial role in improving patient safety and care team efficiency while reducing the growing concerns of alarm fatigue.

"Real-time communication requires seamless integration between systems to ensure clinicians have the right information at the right time to optimize workflow, improve patient care and safety, and reduce costs," said Gautam M. Shah, vice president of product management at Vocera.

"The Vocera Clinical Workflow Engine allows the Vocera Communication System to operate as a single-source for clinical integrations, simplifying and improving the accuracy and efficiency of communication, data flow, reporting and analytics."

For more about Vocera Clinical Workflow Engine, please visit http://www.vocera.com/resource/vocera-clinical-workflow-engine-solution-brief.

 

About Vocera

Vocera Communications, Inc. (NYSE:VCRA) is a mobile healthcare communications company that provides enterprise-class solutions. Widely recognized for developing smarter ways to communicate, Vocera helps care teams collaborate more efficiently by delivering the right information, to the right person, on the right device, at the right time, anywhere. Vocera solutions are installed in more than 1,200 organizations worldwide, improving quality, efficiency, safety and outcomes. Via the company's research collaborative, the Experience Innovation Network, Vocera also drives thought leadership for the healthcare industry and new standards in care delivery to elevate patient, family, nurse and physician experiences. Vocera is headquartered in San Jose, California, with offices in San Francisco, Tennessee, Canada, India, United Arab Emirates, and the United Kingdom.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.